+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myopia - Pipeline Insight, 2021

  • PDF Icon

    Clinical Trials

  • May 2021
  • Region: Global
  • DelveInsight
  • ID: 4989072
This “Myopia - Pipeline Insight, 2021,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Myopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Myopia Understanding

Myopia: Overview

Myopia, commonly referred to as shortsightedness, is a common cause of visual disability throughout the world. The prevalence of myopia varies by country and by ethnic group, reaching as high as 70-90% in some Asian populations. Myopia occurs if the eyeball is too long or the cornea (the clear front cover of the eye) is too curved. As a result, the light entering the eye isn't focused correctly, and distant objects look blurred. While the exact cause of myopia is unknown, there is significant evidence that many people inherit myopia, or at least the tendency to develop myopia. People with myopia can have difficulty clearly seeing a movie or TV screen, a whiteboard in school or while driving. Generally, myopia first occurs in school-age children. Because the eye continues to grow during childhood, it typically progresses until about age 20. However, myopia may also develop in adults due to visual stress or health conditions such as diabetes. Testing for myopia may use several procedures to measure how the eyes focus light and to determine the power of any optical lenses needed to correct the reduced vision. Glasses or contact lenses can correct myopia in children and adults. For adults only (with rare exceptions for children), there are several types of refractive surgeries that can also correct myopia.

"Myopia - Pipeline Insight, 2021" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Myopia pipeline landscape is provided which includes the disease overview and Myopia treatment guidelines. The assessment part of the report embraces, in depth Myopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myopia R&D. The therapies under development are focused on novel approaches to treat/improve Myopia.

Myopia Emerging Drugs Chapters

This segment of the Myopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myopia Emerging Drugs

MicroPine: Eyenovia

Atropine ophthalmic solution, known as MicroPine in US, is developed by Eyenovia, Inc. for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. It is designed based on Eyenovia's Optejet microdose formulation and delivery platform using its patented high-precision piezo-print technology known as MAP (microdose array print) to deliver 6-8 µL of drug, consistent with the capacity of the tear film of the eye. Microdose administration of the drug is anticipated to result in low systemic and ocular drug exposure while improving comfort and ease-of-use in children. Atropine micro-formulation licensed to Arctic vision in China, Hong Kong, Macau, Taiwan and South Korea. Atropine micro-formulation licensed to Bausch Health in USA and Canada. The atropine micro formulation is being evaluated in Phase III clinical trials.
  • NVK002; Nevakar
Nevakar is developing NVK-002, a novel, investigational, preservative-free low-dose atropine eye drop which is administered nightly, as a single drop to both eyes. NVK-002 uses Nevakar's proprietary technology, designed for maximum stability and tolerability. Nevakar is currently testing two concentrations in the US and Europe in multiple clinical studies. The product is being studied for up to 4 years to evaluate if it is safe and effective.

Myopia: Therapeutic Assessment

This segment of the report provides insights about the different Myopia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myopia

There are approx. 6+ key companies which are developing the therapies for Myopia. The companies which have their Myopia drug candidates in the most advanced stage, i.e. Phase III include,Eyenovia.


This report covers around 6+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myopia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myopia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myopia drugs.

Myopia Report Insights

  • Myopia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Myopia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Myopia drugs?
  • How many Myopia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myopia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myopia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myopia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Table of Contents


Executive Summary

Myopia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics
  • Comparative Analysis

Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Myopia - Analytical Perspective

In-depth Commercial Assessment
  • Myopia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Myopia Collaboration Deals
  • Company-Company Collaborations (Licensing/Partnering) Analysis
  • Company-University Collaborations (Licensing/Partnering) Analysis

Late Stage Products (Phase III)
  • Comparative Analysis

MicroPine: Eyenovia
  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II/III)
  • Comparative Analysis

SYD-101: Sydnexis
  • Product Description
  • Research and Development
  • Product Development Activities

Early stage products (Phase I)
  • Comparative Analysis

Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products
  • Comparative Analysis

Myopia Key Companies

Myopia Key Products

Myopia- Unmet Needs

Myopia- Market Drivers and Barriers

Myopia- Future Perspectives and Conclusion

Myopia Analyst Views

Myopia Key Companies

AppendixList of Tables
Table 1 Total Products for Myopia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive ProductsList of Figures
Figure 1 Total Products for Myopia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Nevakar
  • Eyenovia
  • Sydnexis
  • Santen Pharmaceutical
  • Ocumension
  • iVeena Delivery Systems